Top in gastroenterology: Gimoti and lanifibranor
The FDA has approved Gimoti nasal spray to relieve symptoms in adults with acute and recurrent diabetic gastroparesis. This was the top story in gastroenterology last week.
Also, the investigational pan-PPAR agonist lanifibranor has met primary and secondary endpoints in phase 2b trials for the treatment of nonalcoholic steatohepatitis, according to Inventiva.
Read these and more stories below.
FDA approves Gimoti for diabetic gastroparesis
Evoke Pharma announced in a press release that the FDA has approved the new drug application for Gimoti nasal spray to relieve symptoms in adults with acute and recurrent diabetic gastroparesis. Read more.
Lanifibranor meets efficacy, safety endpoints in phase 2b NASH trial
Inventiva announced lanifibranor met primary and secondary endpoints in a phase 2b study for treatment of nonalcoholic steatohepatitis, according to speaker at an Inventiva web conference. Read more.
Positive results with new oral microbiome drug for C. diff
Finch Therapeutics announced positive topline results from a randomized controlled trial of CP101 for the prevention of recurrent Clostridioides difficile infection, according to a press release. Read more.
7 recent reports on inflammatory bowel disease
Healio Gastroenterology compiled seven reports on the most recent research on inflammatory bowel disease. Read more.
COVID-19 substantially reduces endoscopy procedures worldwide
New data revealed a substantial decrease in endoscopy procedures around the world of more than 80% during the COVID-19 pandemic. Read more.